Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

rapidSTRIPE H1N1 test for detection of the pandemic swine origin influenza A (H1N1) virus.

Patel P, Graser E, Robst S, Hillert R, Meye A, Hillebrand T, Niedrig M.

J Clin Microbiol. 2011 Apr;49(4):1591-3. doi: 10.1128/JCM.02563-10. Epub 2011 Jan 19.

2.

Importance of erythrocyte band III anion transporter (SLC4A1) on oxalate clearance of calcium oxalate monohydrate stone-formering patients vs. normal controls.

Oehlschläger S, Fuessel S, Meye A, Herrmann J, Lotzkat U, Froehner M, Albrecht S, Wirth MP.

Urology. 2011 Jan;77(1):250.e1-5. doi: 10.1016/j.urology.2010.06.043. Epub 2010 Oct 13.

PMID:
20947140
3.

Serotonin and melatonin do not play a prominent role in the growth of prostate cancer cell lines.

Pirozhok I, Meye A, Hakenberg OW, Fuessel S, Wirth MP.

Urol Int. 2010;84(4):452-60. doi: 10.1159/000296296. Epub 2010 Mar 16.

4.

Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients.

Taubert H, Würl P, Greither T, Kappler M, Bache M, Lautenschläger C, Füssel S, Meye A, Eckert AW, Holzhausen HJ, Magdolen V, Kotzsch M.

Br J Cancer. 2010 Feb 16;102(4):731-7. doi: 10.1038/sj.bjc.6605520. Epub 2010 Jan 5.

5.

Biocompatibility of iron filled carbon nanotubes in vitro.

Taylor A, Lipert K, Krämer K, Hampel S, Füssel S, Meye A, Klingeler R, Ritschel M, Leonhardt A, Büchner B, Wirth MP.

J Nanosci Nanotechnol. 2009 Oct;9(10):5709-16.

PMID:
19908442
6.

Detection of circulating tumor cells in peripheral blood of patients with renal cell carcinoma correlates with prognosis.

Bluemke K, Bilkenroth U, Meye A, Fuessel S, Lautenschlaeger C, Goebel S, Melchior A, Heynemann H, Fornara P, Taubert H.

Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2190-4. doi: 10.1158/1055-9965.EPI-08-1178.

7.

Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease-free interval and the number of metastases per patient.

Wuttig D, Baier B, Fuessel S, Meinhardt M, Herr A, Hoefling C, Toma M, Grimm MO, Meye A, Rolle A, Wirth MP.

Int J Cancer. 2009 Jul 15;125(2):474-82. doi: 10.1002/ijc.24353.

8.

Role of cellular oxalate in oxalate clearance of patients with calcium oxalate monohydrate stone formation and normal controls.

Oehlschläger S, Fuessel S, Meye A, Herrmann J, Froehner M, Albrecht S, Wirth MP.

Urology. 2009 Mar;73(3):480-3. doi: 10.1016/j.urology.2008.11.028. Epub 2009 Jan 23.

PMID:
19167040
9.

Multitarget siRNA inhibition of antiapoptotic genes (XIAP, BCL2, BCL-X(L)) in bladder cancer cells.

Kunze D, Wuttig D, Fuessel S, Kraemer K, Kotzsch M, Meye A, Grimm MO, Hakenberg OW, Wirth MP.

Anticancer Res. 2008 Jul-Aug;28(4B):2259-63.

10.

Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array.

Toma MI, Grosser M, Herr A, Aust DE, Meye A, Hoefling C, Fuessel S, Wuttig D, Wirth MP, Baretton GB.

Neoplasia. 2008 Jul;10(7):634-42.

11.

Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo.

Kunze D, Wuttig D, Kausch I, Blietz C, Blumhoff L, Burmeister Y, Kraemer K, Fuessel S, Toma M, Schwenzer B, Meye A, Grimm MO, Hakenberg OW, Jocham D, Wirth MP.

Int J Oncol. 2008 May;32(5):1049-56.

PMID:
18425331
12.

Telomerase inhibition by synthetic nucleic acids and chemosensitization in human bladder cancer cell lines.

Kraemer K, Fuessel S, Meye A.

Methods Mol Biol. 2007;405:9-22. doi: 10.1007/978-1-60327-070-0_2.

PMID:
18369813
13.

Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor.

Kotzsch M, Sieuwerts AM, Grosser M, Meye A, Fuessel S, Meijer-van Gelder ME, Smid M, Schmitt M, Baretton G, Luther T, Magdolen V, Foekens JA.

Breast Cancer Res Treat. 2008 Sep;111(2):229-40. Epub 2007 Oct 20.

PMID:
17952591
14.

[Multifunctional carbon nano-tubes for biomedical applications (CARBIO). A project of the European Marie Curie Network].

Krämer K, Meye A, Taylor A, Klingeler R, Mönch I, Hampel S, Leonhard A, Büchner B, Kunze D, Unversucht S, Füssel S, Wirth MP.

Urologe A. 2007 Sep;46(9):1248. German. No abstract available.

PMID:
17671776
15.

[In vitro and in vivo evaluation of inhibitory nucleic acid constructs for specific therapy of human urinary bladder carcinoma].

Kunze D, Füssel S, Meye A, Wuttig D, Krämer K, Kotzsch M, Toma M, Schwenzer B, Kausch I, Jocham D, Hakenberg OW, Grimm MO, Wirth MP.

Urologe A. 2007 Sep;46(9):1289. German. No abstract available.

PMID:
17665160
16.

[Comparative evaluation of expression patterns of established and new prostate carcinoma associated genes with reference to suitability for molecular biologic diagnostic and prognostic factors].

Füssel S, Unversucht S, Meye A, Kunze D, Baretton G, Toma M, Haase M, Grimm MO, Seifert J, Höfling C, Koch R, Wirth MP.

Urologe A. 2007 Sep;46(9):1088-9. German. No abstract available.

PMID:
17624512
17.

[Transcriptome expression analyses of pulmonary renal cell carcinoma metastases].

Wuttig D, Höfling C, Füssel S, Meinhardt M, Herr A, Tennstedt P, Holotiuk O, Baretton G, Meye A, Grimm MO, Rolle A, Wirth MP.

Urologe A. 2007 Sep;46(9):1291-2. German. No abstract available.

PMID:
17619850
18.

Stem cell-associated genes are extremely poor prognostic factors for soft-tissue sarcoma patients.

Taubert H, Würl P, Greither T, Kappler M, Bache M, Bartel F, Kehlen A, Lautenschläger C, Harris LC, Kaushal D, Füssel S, Meye A, Böhnke A, Schmidt H, Holzhausen HJ, Hauptmann S.

Oncogene. 2007 Nov 1;26(50):7170-4. Epub 2007 May 21.

PMID:
17525744
19.

Are overexpressed alternative survivin transcripts in human bladder cancer suitable targets for siRNA-mediated in vitro inhibition?

Wuttig D, Kunze D, Fuessel S, Toma M, Stade J, Kotzsch M, Kappler M, Taubert H, Schwenzer B, Baretton G, Hakenberg OW, Meye A, Wirth MP.

Int J Oncol. 2007 Jun;30(6):1317-24.

PMID:
17487351
20.

Expression of the stem cell self-renewal gene Hiwi and risk of tumour-related death in patients with soft-tissue sarcoma.

Taubert H, Greither T, Kaushal D, Würl P, Bache M, Bartel F, Kehlen A, Lautenschläger C, Harris L, Kraemer K, Meye A, Kappler M, Schmidt H, Holzhausen HJ, Hauptmann S.

Oncogene. 2007 Feb 15;26(7):1098-100. Epub 2006 Sep 4.

PMID:
16953229
21.

Synthetic nucleic acids as potential therapeutic tools for treatment of bladder carcinoma.

Fuessel S, Meye A, Kraemer K, Kunze D, Hakenberg OW, Wirth MP.

Eur Urol. 2007 Feb;51(2):315-26; discussion 326-7. Epub 2006 Aug 11. Review.

PMID:
16935415
22.

Quantitative multi-gene expression profiling of primary prostate cancer.

Schmidt U, Fuessel S, Koch R, Baretton GB, Lohse A, Tomasetti S, Unversucht S, Froehner M, Wirth MP, Meye A.

Prostate. 2006 Oct 1;66(14):1521-34.

PMID:
16921506
23.

Wavelength-dependent induction of CYP24A1-mRNA after UVB-triggered calcitriol synthesis in cultured human keratinocytes.

Bär M, Domaschke D, Meye A, Lehmann B, Meurer M.

J Invest Dermatol. 2007 Jan;127(1):206-13. Epub 2006 Aug 10.

24.

Functional analyses of C13orf19/P38IP in prostate cell lines.

Kunze D, Fuessel S, Meye A, Wirth MP, Schmidt U.

Oncol Rep. 2006 Jun;15(6):1599-604.

PMID:
16685401
25.

Microarray analyses in bladder cancer cells: inhibition of hTERT expression down-regulates EGFR.

Kraemer K, Schmidt U, Fuessel S, Herr A, Wirth MP, Meye A.

Int J Cancer. 2006 Sep 15;119(6):1276-84.

26.

Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial.

Fuessel S, Meye A, Schmitz M, Zastrow S, Linné C, Richter K, Löbel B, Hakenberg OW, Hoelig K, Rieber EP, Wirth MP.

Prostate. 2006 Jun 1;66(8):811-21.

PMID:
16482569
27.

Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA.

Fuessel S, Herrmann J, Ning S, Kotzsch M, Kraemer K, Schmidt U, Hakenberg OW, Wirth MP, Meye A.

Cancer Lett. 2006 Feb 8;232(2):243-54.

PMID:
16458121
28.
29.

Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer.

Kotzsch M, Farthmann J, Meye A, Fuessel S, Baretton G, Tjan-Heijnen VC, Schmitt M, Luther T, Sweep FC, Magdolen V, Span PN.

Eur J Cancer. 2005 Nov;41(17):2760-8. Epub 2005 Oct 26.

PMID:
16256342
30.

Detection of circulating tumor cells from renal carcinoma patients: experiences of a two-center study.

Blümke K, Bilkenroth U, Schmidt U, Melchior A, Füssel S, Bartel F, Heynemann H, Fornara P, Taubert H, Wirth MP, Meye A.

Oncol Rep. 2005 Oct;14(4):895-9.

PMID:
16142348
31.

Tissue factor and tumor: clinical and laboratory aspects.

Förster Y, Meye A, Albrecht S, Schwenzer B.

Clin Chim Acta. 2006 Feb;364(1-2):12-21. Epub 2005 Sep 2. Review.

PMID:
16139825
32.

Transcript quantification of Dresden G protein-coupled receptor (D-GPCR) in primary prostate cancer tissue pairs.

Fuessel S, Weigle B, Schmidt U, Baretton G, Koch R, Bachmann M, Rieber EP, Wirth MP, Meye A.

Cancer Lett. 2006 May 8;236(1):95-104. Epub 2005 Jun 27.

PMID:
15979782
33.

Quantification of C13orf19/P38IP mRNA expression by quantitative real-time PCR in patients with urological malignancies.

Schmidt U, Fuessel S, Haase M, Kraemer K, Meye A, Wirth MP.

Cancer Lett. 2005 Jul 28;225(2):253-60. Epub 2004 Dec 9.

PMID:
15978328
34.

Expression of Ki-67 in squamous cell carcinoma of the penis.

Berdjis N, Meye A, Nippgen J, Dittert D, Hakenberg O, Baretton GB, Wirth MP.

BJU Int. 2005 Jul;96(1):146-8.

35.

Vascular endothelial growth factor antisense pretreatment of bladder cancer cells significantly enhances the cytotoxicity of mitomycin C, gemcitabine and Cisplatin.

Krause S, Förster Y, Kraemer K, Fuessel S, Kotzsch M, Schmidt U, Wirth MP, Meye A, Schwenzer B.

J Urol. 2005 Jul;174(1):328-31.

PMID:
15947684
36.

Elevated expression of survivin-splice variants predicts a poor outcome for soft-tissue sarcomas patients.

Taubert H, Kappler M, Bache M, Bartel F, Köhler T, Lautenschläger C, Blümke K, Würl P, Schmidt H, Meye A, Hauptmann S.

Oncogene. 2005 Aug 4;24(33):5258-61.

PMID:
15856009
37.

D-TMPP: a novel androgen-regulated gene preferentially expressed in prostate and prostate cancer that is the first characterized member of an eukaryotic gene family.

Kiessling A, Weigle B, Fuessel S, Ebner R, Meye A, Rieger MA, Schmitz M, Temme A, Bachmann M, Wirth MP, Rieber EP.

Prostate. 2005 Sep 1;64(4):387-400.

PMID:
15761874
38.

Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma.

Hakenberg OW, Fuessel S, Richter K, Froehner M, Oehlschlaeger S, Rathert P, Meye A, Wirth MP.

Urology. 2004 Dec;64(6):1121-6.

PMID:
15596183
39.

Chemosensitization of bladder cancer cell lines by human telomerase reverse transcriptase antisense treatment.

Kraemer K, Fuessel S, Kotzsch M, Ning S, Schmidt U, Wirth MP, Meye A.

J Urol. 2004 Nov;172(5 Pt 1):2023-8.

PMID:
15540782
40.

Induction of proliferation and differentiation of cultured urothelial cells on acellular biomaterials.

Ram-Liebig G, Meye A, Hakenberg OW, Haase M, Baretton G, Wirth MP.

BJU Int. 2004 Oct;94(6):922-7.

41.

siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth.

Ning S, Fuessel S, Kotzsch M, Kraemer K, Kappler M, Schmidt U, Taubert H, Wirth MP, Meye A.

Int J Oncol. 2004 Oct;25(4):1065-71.

PMID:
15375557
42.

D-GPCR: a novel putative G protein-coupled receptor overexpressed in prostate cancer and prostate.

Weigle B, Fuessel S, Ebner R, Temme A, Schmitz M, Schwind S, Kiessling A, Rieger MA, Meye A, Bachmann M, Wirth MP, Rieber EP.

Biochem Biophys Res Commun. 2004 Sep 10;322(1):239-49.

PMID:
15313197
43.

Antisense-mediated VEGF suppression in bladder and breast cancer cells.

Förster Y, Meye A, Krause S, Schwenzer B.

Cancer Lett. 2004 Aug 20;212(1):95-103.

PMID:
15246565
44.

Comparative evaluation of microsatellite marker, AP-PCR and CGH studies in primary renal cell carcinoma.

Hoefling C, Schmidt H, Meinhardt M, Lohse A, Taubert H, Fuessel S, Schmidt U, Schuster K, Baretton G, Wirth MP, Meye A.

Int J Mol Med. 2004 Jun;13(6):835-42.

PMID:
15138621
45.

Quantification of disseminated tumor cells in the bloodstream of patients with hormone-refractory prostate carcinoma undergoing cytotoxic chemotherapy.

Schmidt U, Bilkenroth U, Linné C, Fuessel S, Kraemer K, Froehner M, Wirth MP, Meye A.

Int J Oncol. 2004 Jun;24(6):1393-9.

PMID:
15138579
46.

Systematic in vitro evaluation of survivin directed antisense oligodeoxynucleotides in bladder cancer cells.

Fuessel S, Kueppers B, Ning S, Kotzsch M, Kraemer K, Schmidt U, Meye A, Wirth MP.

J Urol. 2004 Jun;171(6 Pt 1):2471-6.

PMID:
15126878
47.

Adult prostate sarcoma diagnosed from tissue spontaneously excreted through the urethra.

Froehner M, Bartholdt E, Meye A, Manseck A, Wirth MP.

Urol Oncol. 2004 Mar-Apr;22(2):119-20.

PMID:
15082008
48.

D-PCa-2: a novel transcript highly overexpressed in human prostate and prostate cancer.

Weigle B, Kiessling A, Ebner R, Fuessel S, Temme A, Meye A, Schmitz M, Rieger MA, Ockert D, Wirth MP, Rieber EP.

Int J Cancer. 2004 May 10;109(6):882-92.

49.

Detection of disseminated tumor cells in peripheral blood of patients with breast cancer: correlation to nodal status and occurrence of metastases.

Taubert H, Blümke K, Bilkenroth U, Meye A, Kutz A, Bartel F, Lautenschläger C, Ulbrich EJ, Nass N, Holzhausen HJ, Koelbl H, Lebrecht A.

Gynecol Oncol. 2004 Jan;92(1):256-61.

PMID:
14751168
50.

Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53.

Kappler M, Bache M, Bartel F, Kotzsch M, Panian M, Würl P, Blümke K, Schmidt H, Meye A, Taubert H.

Cancer Gene Ther. 2004 Mar;11(3):186-93.

PMID:
14739938

Supplemental Content

Support Center